BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

10604	Companies
225013	Keywords
153734	Articles
119072	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 12/17/2025 at 09:05, 6 months 4 days ago

Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
BioNxt Solutions Inc. announces breakthrough in drug delivery for dysphagia, securing first national-level patent for thin-film platform, targeting autoimmune markets with bioequivalent cladribine treatment

BioNxt Solutions Inc. Drug Delivery Dysphagia Thin-film Platform Autoimmune Markets
BRIEF

published on 12/09/2025 at 09:10, 6 months 12 days ago

BioNxt Develops "Melt in Your Mouth" Cladribine for MS Patients

Multiple Sclerosis Cladribine BioNxt Solutions Melt In Your Mouth Drug-delivery
BRIEF

published on 12/09/2025 at 09:10, 6 months 12 days ago

BioNxt développe une cladribine « fondante » pour les patients atteints de SEP.

Sclérose En Plaques Cladribine Solutions BioNxt Administration De Médicaments Fond Dans La Bouche
PRESS RELEASE

published on 12/09/2025 at 09:05, 6 months 12 days ago

BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
BioNxt Solutions Inc. is developing a sublingual cladribine ODF to enhance MS treatment access. The innovative technology aims to improve swallowing difficulties and increase therapy adherence

BioNxt Solutions Inc. Multiple Sclerosis Drug Delivery Cladribine ODF Melt In Your Mouth
BRIEF

published on 12/01/2025 at 09:10, 6 months 20 days ago

BioNxt Solutions va acquérir la propriété intellectuelle d'un médicament de chimiothérapie sublinguale

Propriété Intellectuelle Chimiothérapie Solutions BioNxt Médicament Sublingual Marché Des Immunosuppresseurs
BRIEF

published on 12/01/2025 at 09:10, 6 months 20 days ago

BioNxt Solutions to Acquire IP for Sublingual Chemotherapy Drug

Intellectual Property Chemotherapy BioNxt Solutions Sublingual Drug Immunosuppressant Market
PRESS RELEASE

published on 12/01/2025 at 09:05, 6 months 20 days ago

BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
BioNxt Solutions collaborates with European chemotherapy company for novel sublingual drug formulation with high-potency ingredient. Focus on oncology and immunosuppressant treatments. Company plans to expand IP portfolio

Oncology BioNxt Solutions European Chemotherapy Company Sublingual Drug Formulation Immunosuppressant
BRIEF

published on 11/20/2025 at 09:10, 7 months 1 day ago

BioNxt Receives Eurasian Patent for Sublingual Cladribine Platform

Global Market Autoimmune Diseases Patent Grant BioNxt Solutions Sublingual Cladribine
BRIEF

published on 11/20/2025 at 09:10, 7 months 1 day ago

BioNxt obtient un brevet eurasien pour sa plateforme de cladribine sublinguale

Marché Mondial Maladies Auto-immunes Solutions BioNxt Cladribine Sublinguale Brevet Accordé
PRESS RELEASE

published on 11/20/2025 at 09:05, 7 months 1 day ago

BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
BioNxt Solutions Inc. receives Eurasian Patent No. 051510 for sublingual anticancer drug delivery system, a key milestone in global IP strategy. Expansion to EU and US markets in progress

BioNxt Solutions Inc. Sublingual Delivery Eurasian Patent Pharmaceutical Markets Global IP Strategy

Accesswire

Published on 06/20/2026 at 01:00, 1 day 8 hours ago

Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 9 hours ago

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 2 days 4 hours ago

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 8 hours ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 8 hours ago

Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting

View all ACCESSWIRE

EQS Group

Published on 06/20/2026 at 21:25, 12 hours 3 minutes ago

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 1 day 3 hours ago

Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 13 hours ago

2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 1 day 13 hours ago

2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 1 day 14 hours ago

Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting

Les Echos

Published on 06/19/2026 at 19:33, 1 day 13 hours ago

Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 1 day 13 hours ago

Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day 14 hours ago

Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 1 day 14 hours ago

Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/19/2026 at 19:05, 1 day 14 hours ago

CP - Changement de gouvernance

View all LES ECHOS COMFI WIRE